The vulnerable endothelium: priming the vascular endothelium for thrombosis with unfractionated heparin: biologic plausibility for observations from the Superior Yield of the New Strategy of Enoxaparin, Revascularization and GlYcoprotein IIb/IIIa Inhibitors (SYNERGY) trial.
Publication
, Journal Article
Becker, RC
Published in: American heart journal
August 2005
Duke Scholars
Published In
American heart journal
DOI
EISSN
1097-6744
ISSN
0002-8703
Publication Date
August 2005
Volume
150
Issue
2
Start / End Page
189 / 192
Related Subject Headings
- Vasculitis
- Thrombosis
- Thrombophilia
- Randomized Controlled Trials as Topic
- Premedication
- Myocardial Infarction
- Models, Biological
- Meta-Analysis as Topic
- Lipoproteins
- Humans
Citation
APA
Chicago
ICMJE
MLA
NLM
Becker, R. C. (2005). The vulnerable endothelium: priming the vascular endothelium for thrombosis with unfractionated heparin: biologic plausibility for observations from the Superior Yield of the New Strategy of Enoxaparin, Revascularization and GlYcoprotein IIb/IIIa Inhibitors (SYNERGY) trial. American Heart Journal, 150(2), 189–192. https://doi.org/10.1016/j.ahj.2005.04.006
Becker, Richard C. “The vulnerable endothelium: priming the vascular endothelium for thrombosis with unfractionated heparin: biologic plausibility for observations from the Superior Yield of the New Strategy of Enoxaparin, Revascularization and GlYcoprotein IIb/IIIa Inhibitors (SYNERGY) trial.” American Heart Journal 150, no. 2 (August 2005): 189–92. https://doi.org/10.1016/j.ahj.2005.04.006.
Becker RC. The vulnerable endothelium: priming the vascular endothelium for thrombosis with unfractionated heparin: biologic plausibility for observations from the Superior Yield of the New Strategy of Enoxaparin, Revascularization and GlYcoprotein IIb/IIIa Inhibitors (SYNERGY) trial. American heart journal. 2005 Aug;150(2):189–92.
Becker, Richard C. “The vulnerable endothelium: priming the vascular endothelium for thrombosis with unfractionated heparin: biologic plausibility for observations from the Superior Yield of the New Strategy of Enoxaparin, Revascularization and GlYcoprotein IIb/IIIa Inhibitors (SYNERGY) trial.” American Heart Journal, vol. 150, no. 2, Aug. 2005, pp. 189–92. Epmc, doi:10.1016/j.ahj.2005.04.006.
Becker RC. The vulnerable endothelium: priming the vascular endothelium for thrombosis with unfractionated heparin: biologic plausibility for observations from the Superior Yield of the New Strategy of Enoxaparin, Revascularization and GlYcoprotein IIb/IIIa Inhibitors (SYNERGY) trial. American heart journal. 2005 Aug;150(2):189–192.
Published In
American heart journal
DOI
EISSN
1097-6744
ISSN
0002-8703
Publication Date
August 2005
Volume
150
Issue
2
Start / End Page
189 / 192
Related Subject Headings
- Vasculitis
- Thrombosis
- Thrombophilia
- Randomized Controlled Trials as Topic
- Premedication
- Myocardial Infarction
- Models, Biological
- Meta-Analysis as Topic
- Lipoproteins
- Humans